Abstract
No public abstract is available from the verified source records.
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Once-weekly semaglutide in adults with overweight or obesity
10.1056/nejmoa2032183 · 2021
Semaglutide and cardiovascular outcomes in obesity without diabetes
10.1056/nejmoa2307563 · 2023
Medicaid coverage for obesity medications: utilization and net-of-rebate spending
2026
U.S. eligibility and preventable cardiovascular, diabetes, and kidney outcomes from semaglutide in the SELECT trial
10.1016/j.jacadv.2025.101773 · 2025
Weight regain after cessation of medication for weight management: systematic review and meta-analysis
10.1136/bmj-2025-085304 · 2026
GLP-1-induced weight loss and the female obesity penalty
2026
Racial and ethnic disparities in opioid access and urine drug screening among older patients with poor-prognosis cancer near the end of life
10.1200/jco.22.01413 · 2023
No additional external references are available.